Thanks for Posting @pinch2020 what a brilliant article ,,, sure Fiona wont be bias toward SNT 6302 but she will certainly bring it to the panels attention..
I Believe Fiona has 6m SNT shares but I'm happy to be corrected... NZT

If you then take her statement from the Phase I SNT 6302

The primary objective of the phase 1 trial was to investigate thesafety and tolerabilityof the novel topical drug treatment . The trial recruited 42 people with a scar that was at least one year old (any type) to participate in the double-blind study over a three-month period and either applied a placebo or cream three times per week. Pharmaxis has officially announced that the trial has met its primary safety objective and two secondary biomarker endpoints in patients with established scars.

Trial key results:

• Well tolerated with a good safety profile
• Marked change in scar composition with 30% reduction in collagen content
• First-ever proof that LOX inhibition reduces skin collagen underpins the expansion of Pharmaxis and Professor Fiona Wood collaboration into new skin fibrosis indications

Fiona shared the following comments about the trial with Pharmaxis:

“This exploratory clinical study has significantly enhanced our understanding of the role of LOX enzymes in scarring and the scar process itself. PXS-6302 safely inhibits these key enzymes to a significant degree and leads directly to an unprecedented change to the scar composition that we have not seen with any other form of treatment

Time to reverse the R&D slide,
Imagine the devastation & the amount of scar material Fiona would have encountered in her career
,,, and SNT 6302 was Unprecedented ..